biosimilar

The biologics licence application of Dr. Reddy’s Laboratories for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a review by the U.S. Food and Drug Administration (U.S. FDA). It follows the acceptance of its…

Aurobindo Pharma subsidiary CuraTeQ Biologics has entered into an exclusive license agreement with U.S. firm BioFactura Inc to commercialise BFI-751, a proposed biosimilar to recombinant monoclonal antibody Stelara (Ustekinumab) that is…

Dr. Reddy’s Laboratories on Monday said its tocilizumab biosimilar candidate, DRL_TC, for treating rheumatoid arthritis, has successfully met its primary and secondary endpoints in a Phase I study. This Phase I study used an intravenous…

Dr. Reddy’s Laboratories shares gained on Monday in the backdrop of the drugmaker announcing successful completion of a phase-1 study of its proposed biosimilar of tocilizumab for use in the treatment of rheumatoid arthritis. DRL_TC, the…

DRL gets rights to commercialise proposed trastuzumab biosimilar in select LatAm, S-E Asia markets. Pharma major Dr. Reddy’s Laboratories has entered into a partnership with Prestige BioPharma under which it will get exclusive rights…